Health News Today banner for November 9, 2026 highlighting the FDA Class 1 surgical IV kit recall, blood pressure target trials, and Medicare drug-pricing lawsuit

Health News Today, Nov 9: FDA Recall, BP, Medicare

Mr Steady Natural Health

23 hours ago

5 min read

Updated: 42 minutes ago

In health news today, a high-priority hospital device recall, major heart outcomes trials, a Medicare lawsuit, and nutrition data bring practical updates for Americans aged 45 to 75. Federal regulators posted a Class 1 safety classification on nearly 40,000 surgical intravenous kits, while studies at the American Heart Association Scientific Sessions clarified blood pressure goals after stroke and decade-long survival with heart stents. Meanwhile, biotech groups sued to halt a Medicare outpatient drug-pricing pilot, and a clinical trial weighed plant protein for weight loss against muscle preservation after 60.

Summary chart of today's 5 health headlines on November 9, 2026 comparing what happened and what it means for adults over 45

FDA Posts Class 1 Recall on Nearly 40,000 Surgical IV Pump Kits

Federal regulators posted a Class 1 medical device recall—the agency's highest risk category—covering 39,708 Cardinal Health Presource procedure kits that contain BD Alaris Pump Infusion Sets for Model 8100 pumps, according to a November 7 U.S. Food and Drug Administration (FDA) notice. Distributed to hospitals in California, Texas, and North Carolina, affected packages include 30,137 surgical, open-heart anesthesia, and maternity kits alongside 9,571 cardiovascular open-heart kits under companion recall Z-0329-2027. Officials warn that certain tubing sets carry updated performance limits involving infusion rate accuracy if fluid bags hang at improper heights, delayed alarms during line blockages, and unintended fluid surges when clinicians clear obstructed lines. Hospitals were instructed to discard discontinued Alaris sets, switch pumps when appropriate, or apply strict bedside flow safeguards.

What it means for you: These recalled kits are used by hospital surgical and anesthesia teams rather than patients at home, so you do not need to check household supplies. Before a planned heart or inpatient surgery, you or a family advocate can ask your care team how they verify intravenous pump safety protocols.

Heart Trials Split on Blood Pressure Goals After Stroke vs. Diabetes

Three clinical trials presented at the American Heart Association Scientific Sessions in Chicago showed that aggressive blood pressure targets perform very differently after a stroke than in type 2 diabetes, STAT News reported November 7 and updated November 8. In the New England Journal of Medicine OPTIMAL-STROKE study, stroke survivors treated to a systolic blood pressure below 120 mm Hg were significantly less likely to die or suffer a repeat stroke, heart attack, or heart failure hospitalization over four years than patients kept below 140 mm Hg, though kidney and electrolyte labs needed monitoring. A separate University of Pennsylvania trial, REDUCE, found that adding an older water pill right after stroke helped more patients reach under 130/80 mm Hg at three months—notable since one in five survivors stops blood pressure medications within a year. Conversely, OPTIMAL-DIABETES found aiming below 120 mm Hg instead of 140 mm Hg did not cut cardiovascular events or deaths in type 2 diabetes.

What it means for you: Ideal blood pressure goals depend on your personal stroke, diabetes, and kidney history rather than a single universal number. Log your home readings and ask your doctor or pharmacist which target range fits your profile before changing any routine.

11-Year Trial Finds Routine Stents Match Meds in Stable Heart Disease

Routine early artery-opening procedures did not help adults with stable chronic coronary disease live longer over roughly a decade than starting with medications and lifestyle care first, according to ISCHEMIA-EXTEND results published November 7 in JAMA on NIH PubMed. Researchers tracked 5,179 adults—median age 64, including 42% with diabetes—across 320 centers in 37 countries with moderate-to-severe reduced heart blood flow on stress testing through December 2025. Participants assigned to routine early angiography plus stenting or bypass surgery alongside medical therapy had an 11-year all-cause death rate of 25.8%, compared with 26.9% among those starting with medications and heart-healthy daily habits while reserving procedures for persistent symptoms. That equaled an estimated 14-day survival difference over 11 years, excluding emergency heart attacks, left main blockages, and uncontrolled chest pain.

What it means for you: While stents and bypass surgery remain vital during heart attacks or for stubborn chest pain, stable coronary blockages often allow time for shared decision-making. Ask your cardiologist how your test results, symptoms, and daily habits weigh into procedural versus medical care.

Biotech Groups Sue to Block Medicare International Drug-Price Pilot

The Biotechnology Innovation Organization (BIO) and two California life-sciences groups filed a federal lawsuit seeking to halt a Medicare pilot that links U.S. prescription payments to lower prices in peer nations, STAT News reported November 7. Filed in the U.S. District Court for the Northern District of California, the complaint targets the Centers for Medicare and Medicaid Services' Global Benchmark for Efficient Drug Pricing demonstration, known as GLOBE. Finalized this fall to test a "most-favored-nation" rebate formula on select Medicare Part B outpatient medications—infusions and injections given in doctors' offices and hospital clinics—the mandatory pilot benchmarks rebates against prices across 19 comparable countries. Although analysts expect the initial pilot footprint to stay narrow, BIO joins PhRMA in arguing that regulators overstepped Medicare's statutory authority without Congress and set a broad pricing precedent.

What it means for you: Court challenges mean clinic drug prices will not shift overnight, yet Part B coinsurance for outpatient infusions remains a major expense after 65. During Medicare Open Enrollment through December 7, ask a counselor or pharmacist how your Medigap or Medicare Advantage plan caps Part B drug costs.

Plant-Protein Diet Aids Weight Loss, With a Muscle Caveat After 60

Swapping meat, dairy, and eggs for whole plant proteins drove substantial weight loss in a 16-week clinical crossover trial, even as physicians urged older adults to guard against muscle loss, Medical News Today reported November 8. Studying 62 overweight adults who followed both a low-fat vegan diet and a Mediterranean plan for 16 weeks each in BMJ Nutrition, Prevention & Health, Dr. Hana Kahleova's team found participants lost an average of 13 pounds (6 kilograms) during the vegan phase despite total protein dropping from 80 grams to 46 grams daily. Weight held steady during the Mediterranean phase, where daily protein stayed near 73 grams from fish, poultry, dairy, and legumes. Outside physicians noted lower calories, minimal added oils, and higher fiber drove much of the vegan loss, warning steep protein cuts can worsen age-related muscle loss (sarcopenia).

What it means for you: Adding beans, lentils, tofu, and whole grains can support healthy weight after 45, whereas adults over 60 often need steady protein and resistance exercise to protect muscle strength. Consult your doctor or a registered dietitian before major diet shifts, especially with diabetes, high triglycerides, or frailty concerns.

Related reading: November 10 GLP-1 and recall briefing.